Currently, Radiometer Solutions, global leader in the development, production and distribution of technologically advanced blood analyzers in the field of gasometry, electrolytes and metabolites, have an production facility (RSOL I) of approx. 3,500 m2 in Poland. After the RSOL II expansion, the total production facility will reach approx. 18,460 m2 and the number of employees will increase from approx. 400 people to approx. 600 people in 2020.

In Algeria, it is estimated that nearly 2 million Algerian citizens suffer from diabetes. A figure that is expected to rise to more than 3 million cases by 2040. Consequently, Novo Nordisk made a decision to invest in a new production facility. The facility is expected to start the production of insulin pens and other medicines for diabetes in August 2019, after having faced a number of constraints related to the purchase of the land and lack of water and electricity.

Coloplast is once again expanding, this time by a new production facility in Costa Rica, the first one of its kind in the American continent. The new production facility is expected to be fully operational in summer 2021. With the new facility in Costa Rica Coloplast’s aim is to increase the global manufacturing capacity and at the same time support the future growth of the market in the Americas.

Iran has a population of around 77 million, of whom 4.6 million people are currently estimated to have diabetes. Of these only 60% (approx. 2.7 million) are diagnosed according to a Novo Nordisk report in 2015.

Aqvila won the design sub-contract for the reinforced concrete structures, primary steel structures, secondary steel structures and façade girts.